peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Bulletin from the Extraordinary General Meeting of Hansa Medical AB (publ)

11 Dec 2018, 13:00
Regulatory information
Lund, Sweden, 11 December 2018 - Hansa Medical AB (PR Newswire) (Nasdaq Stockholm: HMED) (“Hansa Medical” or the “Company”), today held an extraordinary general meeting. The extraordinary general meeting resolved to change Hansa Medical’s company name to Hansa Biopharma AB, in accordance with the board of directors’ proposal.

“The new name Hansa Biopharma emphasizes our focus on the development and commercialization of biological drugs, biopharmaceuticals. This refinement of our profile is particularly important for the continued internationalization of our business and our investor base.” said Søren Tulstrup, President and CEO of Hansa Medical.

Today, the Company has further submitted the resolution and the new company name for registration to the Swedish Companies Registration Office. The launch of the Company’s new name, including updated web page and graphical profile, is expected to take place on or about the beginning of 2019.

The information was submitted for publication, through the agency of the contact persons set out below, on December 11, 2018 at 1:00pm CET.

For further information, please contact:

Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ)
Mobile: +46 707 175477

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations
FTI Consulting
Simon Conway/ Stephanie Cuthbert 
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks/ David Rosen (media)
+1 212 600 1902

About Hansa Medical
Hansa Medical (NASDAQ Stockholm: HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.